Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861957 | 0.87 | LMNA (0.77) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL4362133 | 0.83 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL15688075 | 0.83 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL521635 | 0.83 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1KDM4ECYP2A13 | |
| SCHEMBL13861955 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL13861956 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL3156625 | 0.79 | KDM4E (1.00) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL4369274 | 0.76 | ALDH1A1 (0.65) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2209503 | 0.75 | LMNA (0.60) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL14768636 | 0.75 | LMNA (0.59) | LMNASMN1; SMN2ALDH1A1KDM4ECTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8563544-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | LMNA 4120/4885SMN1; SMN2 603/4885ALDH1A1 1349/4885 |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | LMNA 4120/4885SMN1; SMN2 603/4885ALDH1A1 1349/4885 |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | LMNA 4120/4885SMN1; SMN2 603/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.